# A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

> **NCT01579461** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 32 (actual)

## Conditions studied

- Pharmacokinetics
- Healthy Subjects
- Mild and Moderate Hepatic Impairment

## Interventions

- **DRUG:** mirabegron

## Key facts

- **NCT ID:** NCT01579461
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579461, "A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01579461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*